FIGURE 2.

miR‐126 KO perturbs MDS maintenance in vivo. (A) Breeding scheme used to generate NHD13/miR‐126 KO animals. B‐E. PLT counts (B), BM smears(red arrows, dysplasia cells) (C), BM LSK (D) and Ter119⁺ mature erythroid cells (E) in NHD13/miR‐126 KO (n = 3) and NHD13/miR‐126 WT mice (n = 3). F‐I. RBC count, HGB level, PLT count and MCV(F), CD45.2⁺ NHD13⁺ chimerism in BM (G) and PB (H), and the percentage of BM Ter119⁺(I) in secondary recipients receiving with equal numbers of CD45.2⁺ BM cells from either miR‐126 WT or miR‐126 KO NHD13⁺ transgenic mice, at 16 weeks post‐bone marrow transplantation (BMT). Results shown represent mean ± SEM. *P < 0.05, **P < 0.01; by two‐tailed, paired Student's t‐test